Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Jul 7, 2010

News Details

Corporate | 7 July 2010 10:42

Eckert & Ziegler: first patient treated for Brain cancer using IsoSeed(R)

Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous

07.07.2010 10:42

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 07.07.2010. The Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a firm specializing in medical use
of radioactivity, has delivered for the first time through its Belgian
subsidiary IBt Bebig its product IsoSeed(R) for the treatment of a brain
tumor patient in the Helsinki University Central Hospital, Finland.

Low radioactive, miniaturized seeds are used for brachytherapy, a treatment
method where the radiation source is placed inside or next to the area
requiring treatment. The intracerebral implantation of Iodine-125 seeds
through a stereotactic guiding system puts seeds in an exactly defined
tumor volume where they fight directly the tumor while sparing the healthy
tissue. Compared to conventional radiation therapy techniques the use of
radioactive implants shows significant economic and clinical advantages. On
the one hand brachytherapy does not require large capital investments in
treatment devices, on the other hand the implantation of seeds results in a
significantly prolonged survival.

The miniaturized IsoSeed(R) is today mostly used to treat early stage
prostate cancer but is also registered for the treatment of other tumors.

'We are proud to see such a prestigious institution using our seeds. Like
for the Breast Brachytherapy potential we were announcing recently, we look
forward for the growing interest towards using IBt Bebig seeds for brain
tumors. IBt Bebig is committed to help finding new ways to use
brachytherapy as a treatment option', said Dr. Edgar Löffler, member of the
Board of Directors and reponsible for the Therapy segment.

The Eckert & Ziegler Group, with around 520 employees, is one of the
world's largest providers of isotope technology components for radiotherapy
and nuclear medicine.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Tel.: +49 (0) 30 / 94 10 84-138, Fax
-112, E-Mail: karolin.riehle@ezag.de, www.ezag.com

07.07.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg

End of News DGAP News-Service

---